<DOC>
	<DOCNO>NCT02509559</DOCNO>
	<brief_summary>The main objective present study combine two line research , investigate interaction emotional processing memory performance ( behavioral electrophysiological level ) modulation ß-blockade . Concerning pharmacological manipulation ß-blockers , study , investigated effect propranolol electrophysiological ( ERPs ) behavioral measure recognition memory along codependence individual variation adrenergic receptor ' polymorphism . Till , also find genetic influence ADRB1 ADRB2 recognition memory emotional content lack . Therefore , current investigation design replicate former result reveal reduced ERP correlate recognition memory emotional picture due administration ß-blocker propranolol . Furthermore investigator goal test , whether difference carrier genetic variant ADRB1 ADRB2 memory performance and/or change event-related potential propranolol influence mention process . In conclusion , investigator hypothesize : ( 1 ) memory advantage emotionally arouse stimulus emotionally neutral picture ; ( 2 ) pronounce ERP component ( EPN , LPP , old-new effect ) associate encode memory emotional stimulus ; ( 3 ) reduction electrocortical correlate emotional recognition memory ( old-new effect ) cause propranolol ; ( 4 ) potential impact genetic variant ADRB1 ADRB2 emotional information process memory formation alone , propranolol modulation process . Furthermore , investigator hypothesize additional pharmacodynamic effect propranolol influence skin- conductance , pulse wave , burden heart frequency , pulmonary function metabolomics , might depend ADRB1 ADRB2 genotype .</brief_summary>
	<brief_title>Effects Propranolol ( v . Placebo ) Information Processing During Presentation Emotionally Arousing Pictures</brief_title>
	<detailed_description />
	<mesh_term>Propranolol</mesh_term>
	<criteria>18 35 year male caucasian body mass index : &gt; 19 kg/m² &lt; 27 kg/m² genotype : 1. homozygote ADRB2 haplotype 2 ( variant allele ) homozygote ADRB1 c.1165 ( CC ) 2. homozygote ADRB2 haplotype 2 ( variant allele ) homozygote ADRB1 c.1165 ( GG ) heterozygote ADRB1 c.1165 ( CG ) 3. homozygote ADRB2 haplotype 4 ( wildtype ) homozygote ADRB1 c.1165 ( CC ) 4. homozygote ADRB2 haplotype 4 ( wildtype ) homozygote ADRB1 c.1165 ( GG ) heterozygote ADRB1 c.1165 ( CG ) good health evidence result clinical examination , ECG , ergometry laboratory checkup , judge clinical investigator differ clinical relevant way normal state ; low limit systolic pressure state 110 mm Hg diastolic blood pressure 70 mmHg well heart frequency fall 50 bpm ( WHO definition ) write informed consent sex : female hepatic renal disease and/or pathological finding , might interfere pharmacokinetics pharmacodynamics study medication exist cardiac hematological disease and/or pathological finding , might interfere drug 's safety , tolerability and/or pharmacokinetics ( e.g . bradycardia , hypotonia , av block I° ) volunteer liable orthostatic dysregulation , fainting , blackouts peripheral circulatory disturbance gastrointestinal disease and/or pathological finding ( e.g . stenosis ) , might interfere pharmacokinetics pharmacodynamics study medication obstructive disorder breathing ( e. g. asthma bronchiale ) know allergic reaction active ingredient use constituent study medication know allergic reaction drug therapy anamnesis actual deallergisation psoriasis diabetes mellitus addiction hypoglycemia pheochromocytoma myasthenia gravis drug alcohol dependence positive drug alcohol screen smoker 10 cigarette per day positive result HIV , HBV HCV screen volunteer diet could affect pharmacokinetics drug ( e. g. vegetarian heavy tea coffee drinker ( 1L per day ) volunteer suspect know follow instruction clinical investigator volunteer unable understand write verbal instruction , particular regard risk inconvenience expose result participation study le 14 day last acute disease medication within 4 week prior intend first administration study medication might influence function gastrointestinal tract ( e.g . laxative , metoclopramide , loperamide , antacid , H2receptor antagonists , proton pump inhibitor , anticholinergic ) medication within two week prior first administration study medication , least 10time halflive respective drug ( except oral contraceptive ) intake grapefruit contain food beverage within 14 day prior administration study medication intake poppy seed contain food beverage within 14 day prior administration study medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Receptors , Adrenergic</keyword>
	<keyword>Propranolol</keyword>
</DOC>